These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15375541)

  • 1. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
    Basu S; Brown JE; Flannigan GM; Gill JH; Loadman PM; Martin SW; Naylor B; Puri R; Scally AJ; Seargent JM; Shah T; Phillips RM
    Int J Oncol; 2004 Oct; 25(4):921-7. PubMed ID: 15375541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.
    Basu S; Brown JE; Flannigan GM; Gill JH; Loadman PM; Martin SW; Naylor B; Scally AJ; Seargent JM; Shah T; Puri R; Phillips RM
    Int J Cancer; 2004 May; 109(5):703-9. PubMed ID: 14999778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP.
    Phillips RM; Basu S; Brown JE; Flannigan GM; Loadman PM; Martin SW; Naylor B; Puri R; Shah T
    Int J Oncol; 2004 Apr; 24(4):1005-10. PubMed ID: 15010841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
    Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
    Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
    Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
    Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
    Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
    Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo(1).
    Phillips RM; Burger AM; Fiebig HH; Double JA
    Biochem Pharmacol; 2001 Nov; 62(10):1371-7. PubMed ID: 11709197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.
    Song SY; Jeong SY; Park HJ; Park SI; Kim DK; Kim YH; Shin SS; Lee SW; Ahn SD; Kim JH; Lee JS; Choi EK
    Lung Cancer; 2010 May; 68(2):278-82. PubMed ID: 19596483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
    Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
    Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].
    Zhang JH; Li Y; Wang R; Sarbia M; Guo W; Wen DG; Wei LZ; Chen ZF; Kuang G; Zhang LW; He M; Wu ML; Wang SJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):544-6. PubMed ID: 14669229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
    Lin YL; Ho IC; Su PF; Lee TC
    Toxicol Appl Pharmacol; 2006 Aug; 214(3):309-17. PubMed ID: 16494910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailoring targeted therapy to individual patients: lessons to be learnt from the development of mitomycin C.
    Volpato M; Phillips RM
    Cancer Genomics Proteomics; 2007; 4(3):175-86. PubMed ID: 17878521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
    Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
    Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.
    Fleming RA; Drees J; Loggie BW; Russell GB; Geisinger KR; Morris RT; Sachs D; McQuellon RP
    Pharmacogenetics; 2002 Jan; 12(1):31-7. PubMed ID: 11773862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.
    Lyn-Cook BD; Yan-Sanders Y; Moore S; Taylor S; Word B; Hammons GJ
    Cell Biol Toxicol; 2006 Mar; 22(2):73-80. PubMed ID: 16532285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells.
    Pan SS; Forrest GL; Akman SA; Hu LT
    Cancer Res; 1995 Jan; 55(2):330-5. PubMed ID: 7812966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C.
    Hu LT; Stamberg J; Pan S
    Cancer Res; 1996 Nov; 56(22):5253-9. PubMed ID: 8912865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.